Axillary Hyperhidrosis (Dermatology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Axillary Hyperhidrosis – Drugs In Development, 2021, provides an overview of the Axillary Hyperhidrosis (Dermatology) pipeline landscape.

Axillary hyperhidrosis also referred to as excessive underarm sweating. Excessive sweating in the affected area is caused by over activity of the nerves linked to the sweat glands. Specifically, acetylcholine, a chemical in the body that transmits nerve signals, is released from nerve endings and stimulates secretion of sweat. The condition most frequently develops in adolescence or young adulthood. Treatment includes anticholinergic drugs, surgery and antiperspirants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Axillary Hyperhidrosis – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Axillary Hyperhidrosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 1, 1 and 2 respectively.

Axillary Hyperhidrosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis (Dermatology).

– The pipeline guide reviews pipeline therapeutics for Axillary Hyperhidrosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Axillary Hyperhidrosis (Dermatology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Axillary Hyperhidrosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Axillary Hyperhidrosis (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Axillary Hyperhidrosis (Dermatology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Axillary Hyperhidrosis (Dermatology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Brickell Biotech Inc

DelNova Inc

Dermata Therapeutics Inc

Dermavant Sciences Inc

Dermira Inc

Dr. August Wolff GmbH & Co KG Arzneimittel

Medytox Inc

Revance Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Axillary Hyperhidrosis - Overview

Axillary Hyperhidrosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Axillary Hyperhidrosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Axillary Hyperhidrosis - Companies Involved in Therapeutics Development

Brickell Biotech Inc

DelNova Inc

Dermata Therapeutics Inc

Dermavant Sciences Inc

Dermira Inc

Dr. August Wolff GmbH & Co KG Arzneimittel

Medytox Inc

Revance Therapeutics Inc

Axillary Hyperhidrosis - Drug Profiles

(oxybutynin + pilocarpine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DMT-410 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glycopyrrolate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glycopyrronium tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nivobotulinumtoxin A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ReViVox - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sofpironium bromide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Axillary Hyperhidrosis - Dormant Projects

Axillary Hyperhidrosis - Discontinued Products

Axillary Hyperhidrosis - Product Development Milestones

Featured News & Press Releases

Jun 29, 2021: Brickell Biotech announces final patient completed in first U.S. phase 3 pivotal clinical study and patient enrollment completed in second U.S. phase 3 pivotal clinical study of Sofpironium Bromide Gel, 15% for the treatment of primary axillary hyperhidrosis

Jun 24, 2021: Brickell Biotech announces initiation of a phase 1 study of Sofpironium Bromide Gel in primary palmoplantar hyperhidrosis patients by its development partner, Kaken Pharmaceutical in Japan

Jun 01, 2021: Brickell Biotech announces publication of Japan phase 3 long-term safety and efficacy study results for Sofpironium Bromide Gel, 5% (ECCLOCK) in the Journal of Dermatology

Apr 27, 2021: Brickell Biotech completes patient enrollment in U.S. phase 3 pivotal Cardigan I study of Sofpironium Bromide Gel, 15% for the treatment of primary axillary hyperhidrosis

Apr 23, 2021: Brickell Biotech reports results from U.S. phase 3 open-label, long-term safety study on chronic use of sofpironium bromide gel as a potential treatment for primary axillary hyperhidrosis

Apr 16, 2021: Brickell Biotech announces presentation of US phase 3 open-label long-term safety study results for Sofpironium Bromide Gel at the Late-Breaking Research Program during American Academy of Dermatology’s 2021 VMX

Apr 15, 2021: Brickell Biotech announces publication of its HDSM-Ax patient reported outcome scale validation results in the Journal of Drugs in Dermatology

Mar 05, 2021: Brickell Biotech to host key opinion leader webinar on the hyperhidrosis market

Jan 19, 2021: Brickell Biotech announces publication of Japan pivotal phase 3 study results for Sofpironium Bromide Gel, 5% (ECCLOCK) in the Journal of Dermatology

Dec 07, 2020: Brickell Biotech doses first patient in second U.S. pivotal phase 3 clinical study

Nov 18, 2020: Brickell Biotech announces launch date for sofpironium bromide gel, 5% (ECCLOCK) in Japan by its development partner, Kaken Pharmaceutical

Oct 06, 2020: Brickell Biotech announces initiation of U.S. phase 3 program evaluating sofpironium bromide gel, 15% for the treatment of Primary Axillary Hyperhidrosis

Sep 25, 2020: Brickell Biotech announces approval of sofpironium bromide gel, 5% in Japan for treatment of primary axillary hyperhidrosis received by its development partner, Kaken Pharmaceutical

Aug 31, 2020: Brickell Biotech announces issuance of new composition of matter patent on Sofpironium Bromide by the Japanese Patent Office

Jun 15, 2020: Confirmatory phase 3 study of BBI-4000 meet primary endpoint- Announcement at the 119th Annual Meeting of the Japanese Dermatological Association and the 2020 Annual Meeting of American Academy of Dermatology

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Axillary Hyperhidrosis, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Axillary Hyperhidrosis – Pipeline by Brickell Biotech Inc, 2021

Axillary Hyperhidrosis – Pipeline by DelNova Inc, 2021

Axillary Hyperhidrosis – Pipeline by Dermata Therapeutics Inc, 2021

Axillary Hyperhidrosis – Pipeline by Dermavant Sciences Inc, 2021

Axillary Hyperhidrosis – Pipeline by Dermira Inc, 2021

Axillary Hyperhidrosis – Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, 2021

Axillary Hyperhidrosis – Pipeline by Medytox Inc, 2021

Axillary Hyperhidrosis – Pipeline by Revance Therapeutics Inc, 2021

Axillary Hyperhidrosis – Dormant Projects, 2021

Axillary Hyperhidrosis – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Axillary Hyperhidrosis, 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports